GERN insider trading
NasdaqGS HealthcareGERON CORP — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About GERON CORP
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Company website: www.geron.com
GERN insider activity at a glance
FilingIQ has scored 163 insider transactions for GERN since Mar 13, 2015. The most recent filing in our index is dated Apr 13, 2026.
Across the full history, 9 open-market purchases
and 29 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on GERN insider trades is 60.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest GERN Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading GERN
13F funds holding GERN
Frequently asked
- How many insider trades does FilingIQ track for GERN?
- FilingIQ tracks 163 Form 4 insider transactions for GERN (GERON CORP), covering filings from Mar 13, 2015 onwards. 9 of those were filed in the last 90 days.
- Are GERN insiders net buyers or net sellers?
- Across the full Form 4 history for GERN, 9 transactions (6%) were open-market purchases and 29 (18%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does GERN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is GERN in?
- GERON CORP (GERN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.13B.
Methodology & sources
Every GERN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.